3-(Piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one → 9-(2,2-Dimethyl-propyl)-7-(R)-{2-oxo-2-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-ethyl}-6,7,9,10-tetrahydro-3H-2,3,9-triaza-cyclohepta[e]inden-8-one

HRID 132279

반응식

HRID 132279 반응식
O=C1N(C2CCNCC2)CC2C(=CC=CC=2)N1.Cl[C:19]1[C:27]2[NH:26][N:25]=[CH:24][C:23]=2[C:22]2[CH2:28][N:29]([CH2:54][C:55]([CH3:58])([CH3:57])[CH3:56])[C:30](=[O:53])[C@@H:31]([CH2:33][C:34](=[O:52])[N:35]3[CH2:40][CH2:39][CH:38]([N:41]4[CH2:50][C:49]5[C:44](=[CH:45][CH:46]=[CH:47][CH:48]=5)[NH:43][C:42]4=[O:51])[CH2:37][CH2:36]3)[CH2:32][C:21]=2[CH:20]=1>>[CH3:56][C:55]([CH3:58])([CH3:57])[CH2:54][N:29]1[CH2:28][C:22]2[C:23]3[CH:24]=[N:25][NH:26][C:27]=3[CH:19]=[CH:20][C:21]=2[CH2:32][C@H:31]([CH2:33][C:34](=[O:52])[N:35]2[CH2:36][CH2:37][CH:38]([N:41]3[CH2:50][C:49]4[C:44](=[CH:45][CH:46]=[CH:47][CH:48]=4)[NH:43][C:42]3=[O:51])[CH2:39][CH2:40]2)[C:30]1=[O:53]

참가 물질

3

반응물 2

HCID 110425973-(Piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-oneHCID 688264794-Chloro-9-(2,2-dimethyl-propyl)-7-(R)-{2-oxo-2-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-ethyl}-6,7,9,10-tetrahydro-3H-2,3,9-triaza-cyclohepta[e]inden-8-one

생성물 1

HCID 597319619-(2,2-Dimethyl-propyl)-7-(R)-{2-oxo-2-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-ethyl}-6,7,9,10-tetrahydro-3H-2,3,9-triaza-cyclohepta[e]inden-8-one수율 32%

실험 절차

[9-(2,2-dimethyl-propyl)-8-oxo-3,6,7,8,9,10-hexahydro-2,3,9-triaza-(R)-cyclohepta[e]inden-7-yl]-acetic acid (75 mg, 0.23 mmol) and 4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl) piperidine (65 mg, 0.28 mmol) were combined in a manner analogous to the preparation of 4-Chloro-9-(2,2-dimethyl-propyl)-7-(R)-{2-oxo-2-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-ethyl}-6,7,9,10-tetrahydro-3H-2,3,9-triaza-cyclohepta[e]inden-8-one. Title compound was obtained as a white solid in 32% yield. High resolution MS m/e (M+H)+=543.3084.

출처 및 근거

ORD 기록
ord-a0d16446a6584099b07e64bd747d8dbf
출처 데이터셋
uspto-grants-2008_06
특허 번호
US07384930B2

연결된 노트

불러오는 중…